|
|
Volumn 361, Issue 9352, 2003, Pages 184-
|
|
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DEFERIPRONE;
DEFEROXAMINE;
IRON;
IRON CHELATING AGENT;
PYRIDONE DERIVATIVE;
BETA THALASSEMIA;
CHELATION THERAPY;
HALF LIFE TIME;
HUMAN;
METABOLISM;
METHODOLOGY;
NOTE;
BETA-THALASSEMIA;
CHELATION THERAPY;
DEFEROXAMINE;
HALF-LIFE;
HUMANS;
IRON;
IRON CHELATING AGENTS;
PYRIDONES;
|
|
EID: 0037431883
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(03)12225-8 Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
